Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Cash from Financing Activities: 2020-2025

Historic Cash from Financing Activities for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Sep 2025 value amounting to -$120,000.

  • Insight Molecular Diagnostics' Cash from Financing Activities rose 52.94% to -$120,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $39.2 million, marking a year-over-year increase of 310.84%. This contributed to the annual value of $20.4 million for FY2024, which is 67.64% up from last year.
  • As of Q3 2025, Insight Molecular Diagnostics' Cash from Financing Activities stood at -$120,000, which was down 5.26% from -$114,000 recorded in Q2 2025.
  • In the past 5 years, Insight Molecular Diagnostics' Cash from Financing Activities ranged from a high of $69.9 million in Q1 2021 and a low of -$528,000 during Q3 2022.
  • For the 3-year period, Insight Molecular Diagnostics' Cash from Financing Activities averaged around $6.1 million, with its median value being -$29,000 (2023).
  • Within the past 5 years, the most significant YoY rise in Insight Molecular Diagnostics' Cash from Financing Activities was 36,223.33% (2024), while the steepest drop was 750.00% (2024).
  • Over the past 5 years, Insight Molecular Diagnostics' Cash from Financing Activities (Quarterly) stood at -$269,000 in 2021, then surged by 62.83% to -$100,000 in 2022, then skyrocketed by 70.00% to -$30,000 in 2023, then skyrocketed by 36,223.33% to $10.8 million in 2024, then skyrocketed by 52.94% to -$120,000 in 2025.
  • Its Cash from Financing Activities stands at -$120,000 for Q3 2025, versus -$114,000 for Q2 2025 and $28.6 million for Q1 2025.